CARE BEYOND THE CLINIC
Respiri is leading the way in the development of innovative eHealth solutions that aim to improve the management of chronic and costly respiratory disorders such as asthma.
READ MOREVision
A world without the challenges of asthma.
Mission
To improve asthma management by
extending care beyond the clinic.
Values
We are Respectful
We are Accountable
We are One Team
We are Innovative
ASTHMA CARE BEYOND THE CLINIC
Introducing wheezo™, a new innovative asthma management tool. wheezo is an eHealth app combined with a simple, easy to use, handheld device. wheezo records breathing over 30 seconds and analyses the recording for wheeze. The engaging app also allows users to track other important asthma symptoms, triggers, medication usage, location specific weather and environmental factors (pollen, pollution, air quality).
A breath of fresh air for asthma sufferers
Asthma is one of the world’s most prevalent and debilitating chronic diseases with 339 million people affected by the condition. The University of Washington’s Institute for Health Metrics and Evaluation (IHME) estimates that 420,000 people died from asthma worldwide in 2016.
Respiri shaves costs as wheezo technology continues to be well-received
With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins.
Respiri details ‘exceptional’ cost savings to wheezo production
Special Report: Respiri Limited (ASX:RSH) expects its gross product margins for its wheezos to be 30 per cent higher than forecast, as the eHealth company has devised less-expensive ways to produce the asthma management device.
Respiri ‘pleased’ with wheezo feedback from initial sales and marketing
Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it has received from pharmacists and partner Cipla Australia.
RESPIRI PARTNERS
Carlton Football Club AFLW team
Respiri recently announced its partnership with the Carlton Football Club AFLW for 2021 Season. The partnership announcement will see wheezo supported by the Carlton Football Club AFLW team and bring awareness of the importance of asthma management to the forefront of the community.
Australian Patients Association
Respiri recently announced their partnership with Australian Patients Association (APA) to support patients living with asthma through Respiri’s wheezo Experiential Program. The APA is connected with 1.1 million Australian patients and 15,000 Health Care Practitioners.
Pharmacy Guild Australia
Respiri recently announced the two year agreement with Guild Learning and Development (GuildED) and will collaboratively develop a Continuing Professional Development (CPD) online training course for pharmacists on optimising asthma patient management.
MICHAEL CLARKE
Respiri’s first brand ambassador. Hear from the former
Australian Cricket Captain on why he’s partnered with
Respiri to help bring wheezo to market.
JOIN OUR NEWSLETTER
Be the first to hear of Respiri’s latest news and subscribe to the bi-monthly newsletter here.